Dr. Sighild Lemarchant, Axoltis Pharma – Head of Preclinical R&D, will participate to ENCALS meeting 2022, the Annual Meeting of the European Network to Cure ALS, which will take place in Edinburgh, Scotland, on June 1-3, 2022. Dr. Lemarchant will present a preclinical proof of concept study showing that Axoltis’ peptide NX210c, which is now at clinical stage of development, represents a new promising drug candidate for the treatment of Amyotrophic Lateral Sclerosis.